COMMUNIQUÉS West-GlobeNewswire
-
HWH International Inc. enters into a joint venture to build its travel business in Asia
26/04/2024 - 15:15 -
ONWARD® Medical annonce ses résultats financiers et opérationnels pour l’exercice 2023 et partage les faits qui ont marqué l’exercice 2024 à ce jour
26/04/2024 - 15:17 -
Range Impact Transitions Two Executives to Graphium Biosciences Subsidiary as Part of Proposed Divestiture and Promotes Corporate Controller to Chief Financial Officer
26/04/2024 - 15:20 -
Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments
26/04/2024 - 15:23 -
The Ensign Group Schedules First Quarter Earnings Call for Thursday, May 2, 2024
26/04/2024 - 12:00 -
Novo Nordisk A/S – Total number of voting rights and share capital in Novo Nordisk A/S as of 26 April 2024
26/04/2024 - 12:16 -
Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
26/04/2024 - 12:30 -
Interactive Strength Inc. (Nasdaq: TRNR) Strengthens Balance Sheet by Partially Converting Senior Loan to Equity and Extending the Maturity
26/04/2024 - 13:00 -
Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024
26/04/2024 - 13:00 -
Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024
26/04/2024 - 13:05 -
Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)
26/04/2024 - 13:15 -
Johnson & Johnson receives positive CHMP opinion for RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the first-line treatment of patients with advanced non-small cell lung cancer with activating EGFR exon 20 insertion mutations
26/04/2024 - 13:55 -
Burning Rock Announces ADS Ratio Change
26/04/2024 - 07:59 -
Nexstim Plc Business Update Q1 2024
26/04/2024 - 08:00 -
PCI Biotech Holding ASA - Annual Report 2023
26/04/2024 - 08:08 -
Medigene AG reports Financial Results and Business Update for Q1 2024
26/04/2024 - 09:00 -
Composition of the Nomination Committee of Orion Corporation
26/04/2024 - 10:15 -
Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrants
26/04/2024 - 06:27 -
JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension
26/04/2024 - 07:00
Pages